PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Bibliographic Details
Main Authors:	Ying Zhang, Xiangping Zong, Jiaqi LI, Sixun Jia, Hongzhi Geng, Liangyu Zeng, Qin Yang, Wenzhi Cai, Shuangzhu Liu, Yutong Lu, Lei Yu, Caixia LI, Depei Wu
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000975884.42135.d7

Similar Items

2289
by: David D. Maron, et al.
Published: (2017-09-01)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
by: Hongzhi Geng, et al.
Published: (2023-08-01)

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
by: Ying Zhang, et al.
Published: (2021-05-01)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
by: LI Caixia, et al.
Published: (2023-08-01)

Salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy
by: Nikhil Yegya-Raman, et al.
Published: (2023-03-01)

Selinexor and COVID-19: The Neglected Warden
by: Gomaa Mostafa-Hedeab, et al.
Published: (2022-04-01)

PB2289: TRENDS IN ANTIGEN-NEGATIVE RED BLOOD CELL DISTRIBUTIONS ABOUT TEN THOUSAND THREE HUNDRED WHOLE BLOOD DONATIONS
by: F. Talbi, et al.
Published: (2022-06-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
by: Zixun Yin, et al.
Published: (2021-07-01)

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
by: Ping Li, et al.
Published: (2023-02-01)

Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01)

La nutrice di Saffo in P.Oxy. 2289 e i paralleli omerici nel «Carme dei fratelli»
by: Francesco Sironi
Published: (2016-01-01)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
by: Shinichi Makita, et al.
Published: (2019-02-01)

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
by: Yaqing Cao, et al.
Published: (2019-08-01)

P1217: TARGETING HSP110 IN COMBINATION WITH SELINEXOR IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA AND IN CLASSICAL HODGKIN LYMPHOMA INHIBITS STAT6 ACTIVATION AND IMPAIRS LYMPHOMA CELL GROWTH
by: Manon Durand, et al.
Published: (2023-08-01)

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
by: Xuan Zhou, et al.
Published: (2020-11-01)

Treatment of multiple myeloma with selinexor: a review
by: Qianlei Huang, et al.
Published: (2024-01-01)

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors
by: Adam F. Binder, et al.
Published: (2023-10-01)

In vivo CART cell imaging: Paving the way for success in CART cell therapy
by: Reona Sakemura, et al.
Published: (2021-03-01)

Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma
by: Sonam Mittal, et al.
Published: (2023-09-01)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
by: Patrick J. Stiff, et al.
Published: (2023-09-01)

Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)

Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study
by: Marina Caballero-Bellón, et al.
Published: (2023-08-01)

Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma
by: Hairuo Wen, et al.
Published: (2022-11-01)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
by: Hassan B. Alkhateeb, et al.
Published: (2022-07-01)

S228: POSITRON EMISSION TOMOGRAPHY EVALUATION IN A LARGE GROUP OF PATIENTS AFFECTED BY RELAPSED/REFRACTORY B-CELL LYMPHOMAS TREATED WITH ANTI-19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS THERAPY (CART SIE).
by: Anna Dodero, et al.
Published: (2023-08-01)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
by: Jian Zhang, et al.
Published: (2023-08-01)

Donor T cell chimerism correlates with viral reservoir clearance following allogeneic stem cell transplantation in fully cART-suppressed Mauritian cynomolgus macaques
by: Helen L. Wu, et al.
Published: (2019-12-01)

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
by: Jing Guo, et al.
Published: (2022-01-01)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
by: Cristina Gasparetto, et al.
Published: (2021-02-01)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
by: Barbara Muz, et al.
Published: (2017-08-01)

The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients
by: Minghao Li, et al.
Published: (2022-01-01)

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
by: Josée M. Zijlstra, et al.
Published: (2022-02-01)

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
by: Muhamed Baljevic, et al.
Published: (2022-11-01)

P1440: BTK INHIBITORS IMPROVE CART19 CELL THERAPY BY MODULATING IMMUNE SYSTEM
by: W. Luo, et al.
Published: (2022-06-01)

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation
by: Valentín Ortiz-Maldonado, et al.
Published: (2022-01-01)

Co-infusion of high-dose haploidentical donor cells and CD19-targeted CART cells achieves complete remission, successful donor engraftment and significant CART amplification in advanced ALL
by: Changlin Yu, et al.
Published: (2020-05-01)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
by: Zhitao Ying, et al.
Published: (2021-02-01)

Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma
by: Colton Ladbury, MD, et al.
Published: (2024-04-01)